Selecta Biosciences, Inc.

Momenta Pharmaceuticals, Inc.

Other

Boehringer Ingelheim Pharmaceuticals, Inc.

Cartesian Therapeutics, Inc.

Takashi Kei Kishimoto

Roberto A Maldonado

Christopher C Fraser

Sucharita Roy

Mallikarjun Sundaram

C Frank Bennett

Ganesh Venkataraman

Rene Marc Lemieux

Lloyd Johnston

Robert Rothlein

Ganesh Kaundinya

Birgit Corinna Schultes

He Zhou

Jay Duffner

Josephine S D'Alessandro

Aileen Healy

Edward Cochran

Hans C Reiser

Gary O Caviness

Kathleen Last-Barney

Joseph R Woska, Jr

Roy Sucharita

Earl Sands

Werner Cautreels

Zoya Galcheva-Gargova

Robert A Maldonado

Mallik Sundaram

Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.

Tolerogenic synthetic nanocarriers for allergy therapy

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

Methods and compositions for attenuating anti-viral transfer vector immune responses

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.

Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells

Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.

Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).

Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells

Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.

Methods comprising dosing combinations for reducing undesired humoral immune responses

This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.

Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune tolerance

Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses

Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses

Methods and compositions related to targeting agents to tumor tissue are described.

Tissue targeting

Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.

Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization

Preparations of polysaccharides lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.

Non-anticoagulant polysaccharide compositions

Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.

Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins

Growing community of inventors

Lexington, MA, United States of America

Takashi Kei Kishimoto